Cargando…

The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis

Background: Tumor mutational burden (TMB) is a genomic biomarker that can predict favorable responses to immune checkpoint inhibitors (ICIs). Although we have better understanding of TMB in cancer immunity and cancer immunotherapy, the relationship between TMB and the clinical efficacy of ICIs remai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ning, Biao, Liu, Yixin, Wang, Miao, Li, Yi, Xu, Tianzi, Wei, Yongchang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959431/ https://www.ncbi.nlm.nih.gov/pubmed/35355708 http://dx.doi.org/10.3389/fphar.2022.748674

Ejemplares similares

Efficacy and safety of immune checkpoint inhibitors and targeted therapies in resected melanoma: a systematic review and network meta-analysis
por: Sheng, Feng, et al.
Publicado: (2023)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
por: Wu, Yongfeng, et al.
Publicado: (2019)

Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
por: Ma, Jingxin, et al.
Publicado: (2023)

Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis
por: Qi, Yingjie, et al.
Publicado: (2022)

Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non–Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
por: Chai, Qing-Qing, et al.
Publicado: (2019)

The influence of baseline characteristics on the efficacy of immune checkpoint inhibitors for advanced lung cancer: A systematic review and meta-analysis
por: Xiao, Qionghua, et al.
Publicado: (2022)

Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis
por: Liu, Xiangxing, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
por: Chatrath, Ajay, et al.
Publicado: (2021)

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
por: Moeckel, Camille, et al.
Publicado: (2023)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
por: Liu, Shui, et al.
Publicado: (2022)

Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma
por: Yu, Jing, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils
por: Zhou, Ziwei, et al.
Publicado: (2022)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
por: Lin, Anqi, et al.
Publicado: (2021)

Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhang, Tian, et al.
Publicado: (2022)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
por: Lee, Jii Bum, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Zhao, Jing, et al.
Publicado: (2019)

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
por: Yu, Jiahui, et al.
Publicado: (2023)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies
por: Lu, Jingli, et al.
Publicado: (2019)

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
por: Li, Liu, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis
por: Liu, Zijing, et al.
Publicado: (2023)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
por: Wu, Yihao, et al.
Publicado: (2023)

Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Li, Yan, et al.
Publicado: (2021)

The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis
por: Li, Ping, et al.
Publicado: (2018)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
por: Calvo, Roser
Publicado: (2019)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
por: Zhang, Zeng, et al.
Publicado: (2022)

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
por: Pan, Chaohu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_77ob1q48l4hfb7hpsb6gef5niv